Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global plasmid DNA manufacturing market size was exhibited at USD 11.12 billion in 2022 and is projected to hit around USD 11.12 billion by 2032, growing at a CAGR of 17.64% during the forecast period 2023 to 2032.

plasmid DNA manufacturing market size

Key Pointers:

  • North America dominated the global industry in 2022 and accounted for the largest share of 43.19% of the overall revenue. 
  • Asia Pacific is estimated to be the fastest-growing regional segment with a growth rate of 18.53% from 2023 to 2032 
  • The pre-clinical therapeutics development phase segment is estimated to register the fastest growth rate of more than 18.48% during the forecast period. The clinical therapeutics segment dominated the global industry in 2022 and accounted for the maximum share of 57.17% of the overall revenue.
  •  The cell & gene therapy application segment dominated the global industry market in 2022 and accounted for the maximum share of more than 58.09% of the overall revenue.
  • The cancer disease segment dominated the global industry in 2022 and accounted for the maximum share of more than 37.75% of the overall revenue. The segment is expected to register the fastest growth rate of 18.42% and remain dominant throughout the forecast period. 
  • The GMP grade segment dominated the global industry in 2022 and accounted for the maximum share of more than 84.11% of the overall revenue. 

Plasmid DNA Manufacturing Market Report Scope

Report Coverage Details
Market Size in 2023 USD 2.58 Billion
Market Size by 2032 USD 11.12 Billion
Growth Rate From 2023 to 2032 CAGR of 17.64%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Grade, Development phase, Application, Disease
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled

Charles River Laboratories; VGXI, Inc.; Aldevron; Kaneka Corp.; Nature Technology; Cell and Gene Therapy Catapult; Eurofins Genomics; Lonza; Luminous BioSciences, LLC; Akron Biotech.

 

 

Plasmid DNA plays an important role in the healthcare industry. Today, it is crucial for the development of vaccines and next-generation cell and gene therapies. New plasmid DNA vaccines are now being developed, leading to more efficient and clean manufacturing processes. In the production of vaccines and gene therapies, plasmids are more attractive than recombinant viruses as they can deliver significant amounts of DNA with a low risk of oncogenesis or immunogenicity. Such factors are expected to propel industry growth.

Increasing awareness about cell and gene therapy boosts industry growth. This is mainly due to a rise in cell and gene therapy products accepted to treat various diseases globally and the availability of approved gene therapy products. Plasmid DNA is the base for gene therapies and DNA vaccines for several infectious, genetic, and acquired diseases, enteric pathogens, and influenza. With the rising demand for robust disease treatment therapies, various companies and research organizations are accelerating R&D efforts for advanced therapies that target the cause of disease at a genomic level, resulting in increased demand for plasmid DNA.

For instance, in October 2021, the National Institutes of Health, the FDA, five nonprofit organizations, and ten pharmaceutical companies entered into a partnership to ramp up the development of gene therapies for 30 million individuals in the U.S. who suffer from rare disorders. The outbreak of the COVID-19 pandemic led to an increase in the use of plasmid DNA. The COVID-19 pandemic resulted in extensive research efforts for the development of vaccines against the infection. For instance, in November 2021, Enzychem entered into Manufacturing License and Technology Transfer Agreement with Zydus Cadila to develop a COVID-19 plasmid DNA vaccine in South Korea.

Under this initiative, Zydus provided its technical assistance and manufacturing technology to Enzychem. Increased prevalence of cancer is anticipated to boost the production of plasmid DNA. Plasmid DNA is used in gene therapy to identify and treat illnesses in patients. According to the WHO, cancer is one of the leading causes of death globally and is reported for around 10 million deaths in 2020. The most common cancers are lung, breast, prostate, colon, and rectum cancers. In 2020, around 2.26 million cases of breast cancer were reported.

In addition, emerging companies are entering the industry with advanced technologies to meet the increasing demand and strengthen their position in the global market. For instance, in June 2021, Biotage launched a new automated solution for plasmid DNA purification, Biotage PhyPrep. A new automated solution for plasmid DNA purification saves lab technicians’ time by eliminating the need to perform repetitive, manual work. It also fully utilizes the dual flow chromatography technology of the PhyTip columns to produce supercoiled, endotoxin-free, transfection-grade pDNA.

By Grade Scope By Development Phase By Application Scope By Disease Scope
  • R&D Grade
  • GMP Grade
  • Pre-clinical Therapeutics
  • Clinical Therapeutics
  • Marketed Therapeutics
  • DNA Vaccines
  • Cell & Gene Therapy
  • Immunotherapy
  • Others
  • Infectious Disease
  • Cancer
  • Genetic Disorder

Frequently Asked Questions

The global plasmid DNA manufacturing market size was exhibited at USD 11.12 billion in 2022 and is projected to hit around USD 11.12 billion by 2032

The global plasmid DNA manufacturing market is expected to grow at a compound annual growth rate of 17.64% from 2023 to 2032

Some key players operating in the plasmid DNA manufacturing market include Charles River Laboratories, VGXI, Inc., Aldevron, KANEKA CORPORATION, Nature Technology, Cell and Gene Therapy Catapult, Eurofins Genomics, Lonza, and others.

Key factors that are driving the market growth include increasing awareness about cell and gene therapy. Moreover, increasing demand for plasmid DNA is also estimated to accelerate market growth.

Chapter 1. Executive Summary
                   1.1. Market Summary
Chapter 2. Research Methodology
                   2.1. Information Procurement
                   2.2. Information Or Data Analysis
                   2.3. Market Model
                        2.3.1. Market Analysis, By plasmid DNA manufacturing
                        2.3.2. Market Study, By Grade
                        2.3.3. Regional Analysis
Chapter 3. Market Variables, Trends, & Scope
                   3.1. Market Segmentation & Scope
                   3.2. Market Dynamics
                        3.2.1. Market Drivers Analysis
                             3.2.1.1. Increasing number of patients opting for gene therapy
                             3.2.1.2. Robust Pipeline For Gene Therapies
                             3.2.1.3. Highly Competitive Market And Various Strategies Undertaken By market players
                             3.2.1.2. Increasing demand for plasmid DNA in various medical therapies
                        3.2.2. Market Restraint Analysis
                             3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
                   3.3. Covid-19 Impact
                   3.4. Penetration & Growth Prospect Mapping For Vector Type, 2023
                   3.5. Industry Analysis - Porter’s Five Forces
                   3.6. Swot Analysis, By Factor (Political & Legal, Economic And Technological)
                   3.7. Penetration & Growth Prospect Mapping For Prominent Industry Players, 2023
                   3.8. Manufacturer’s Landscape
                   3.9. Plasmid DNA Manufacturing Capacity Mapping Analysis
                   3.10. List Of Companies With Portfolio Comprising Vector-Based Therapeutic Candidates
                   3.11. List Of Plasmid DNA Manufacturers
Chapter 4. Plasmid DNA Manufacturing Market: Strategic Alliances
                   4.1. Strategic Approaches For Market Scale-Up
                        4.1.1. Partnership Models
                        4.1.2. Acquisition
                        4.1.3. Minority Interest (Ownership)
                        4.1.4. Joint Venture
                        4.1.4. Alliance
                        4.1.6. Franchise
                   4.2. Collaborations In Plasmid DNA Manufacturing Market
Chapter 5. Plasmid DNA Manufacturing Market: Segment Analysis, By Grade, 2020 - 2032
                   5.1. Plasmid DNA Manufacturing Market: Grade Movement Analysis
                   5.2. R&D Grade
                        5.2.1. Global R&D Grade Market 2020 - 2032
                   5.3. GMP Grade
                        5.3.1. Global GMP Grade Market 2020 - 2032
Chapter 6. Plasmid DNA Manufacturing Market: Segment Analysis, By Development Phase, 2020 - 2032
                   6.1. Plasmid DNA Manufacturing Market: Development Phase Movement Analysis
                   6.2. Pre-clinical Therapeutics
                        6.2.1. Global Pre-clinical Therapeutics Market Estimates And Forecast 2020 - 2032
                   6.3. Clinical Therapeutics
                        6.3.1. Global Clinical Therapeutics Market Estimates And Forecast 2020 - 2032
                   6.4. Marketed Therapeutics
                        6.4.1. Global Marketed Therapeutics Market Estimates And Forecast 2020 - 2032
Chapter 7. Plasmid DNA Manufacturing Market: Segment Analysis, By Application, 2020 - 2032
                   7.1. Plasmid DNA Manufacturing Market: Application Movement Analysis
                   7.2. DNA Vaccines
                        7.2.1. Global Plasmid DNA Manufacturing Market For DNA Vaccines, 2020 - 2032
                   7.3. Cell & Gene Therapy
                        7.3.1. Global Plasmid DNA Manufacturing Market For Cell & Gene Therapy 2020 - 2032
                   7.4. Immunotherapy
                        7.4.1. Global Plasmid DNA Manufacturing Market For Immunotherapy, 2020 - 2032
                   7.5. Others
                        7.5.1. Global Plasmid DNA Manufacturing Market For Others, 2020 - 2032
Chapter 8. Plasmid DNA Manufacturing Market: Segment Analysis, By Disease, 2020 - 2032
                   8.1. Plasmid DNA Manufacturing Market: Disease Movement Analysis
                   8.2. Cancer
                        8.2.1. Global Plasmid DNA Manufacturing Market For Cancer, 2020 - 2032
                   8.3. Genetic Disorders
                        8.3.1. Global Plasmid DNA Manufacturing Market For Genetic Disorders, 2020 - 2032
                   8.4. Infectious Diseases
                        8.4.1. Global Plasmid DNA Manufacturing Market For Infectious Diseases, 2020 - 2032
Chapter 9. Regional Business Analysis
                   9.1. Plasmid DNA Manufacturing Market Share By Regional, 2023 & 2032
                        9.1.1 North America
                             9.1.1.1 North America market estimates and forecast, 2020 - 2032
                             9.1.1.2 U.S.
                                  9.1.1.2.1 U.S. market estimates and forecast, 2020 - 2032
                             9.1.1.3 Canada
                                  9.1.1.3.1 Canada market estimates and forecast, 2020 - 2032
                        9.1.2 Europe
                             9.1.2.1 Europe market estimates and forecast, 2020 - 2032
                             9.1.2.2 U.K.
                                  9.1.2.2.1 U.K. market estimates and forecast, 2020 - 2032
                             9.1.2.3 Germany
                                  9.1.2.3.1 Germany market estimates and forecast, 2020 - 2032
                             9.1.2.4 France
                                  9.1.2.4.1 France market estimates and forecast, 2020 - 2032
                             9.1.2.5 Spain
                                  9.1.2.5.1 Spain market estimates and forecast, 2020 - 2032
                             9.1.2.6 Italy
                                  9.1.2.6.1 Italy market estimates and forecast, 2020 - 2032
                        9.1.3 Asia Pacific
                             9.1.3.1 Asia Pacific market estimates and forecast, 2020 - 2032
                             9.1.3.2 Japan
                                  9.1.3.2.1 Japan market estimates and forecast, 2020 - 2032
                             9.1.3.3 China
                                  9.1.3.3.1 China market estimates and forecast, 2020 - 2032
                             9.1.3.4 India
                                  9.1.3.4.1 India market estimates and forecast, 2020 - 2032
                             9.1.3.5 Australia
                                  9.1.3.5.1 Australia market estimates and forecast, 2020 - 2032
                             9.1.3.5 South Korea
                                  9.1.3.5.1 South Korea market estimates and forecast, 2020 - 2032
                        9.1.4 Latin America
                             9.1.4.1 Latin America market estimates and forecast, 2020 - 2032
                             9.1.4.2 Brazil
                                  9.1.4.2.1 Brazil market estimates and forecast, 2020 - 2032
                             9.1.4.3 Mexico
                                  9.1.4.3.1 Mexico market estimates and forecast, 2020 - 2032
                             9.1.4.4 Argentina
                                  9.1.4.4.1 Argentina market estimates and forecast, 2020 - 2032
                        9.1.5 Middle East & Africa
                             9.1.5.1 Middle East & Africa market estimates and forecast, 2020 - 2032
                             9.1.5.2 South Africa
                                  9.1.5.2.1 South Africa market estimates and forecast, 2020 - 2032
                             9.1.5.3 Saudi Arabia
                                  9.1.5.3.1 Saudi Arabia market estimates and forecast, 2020 - 2032
                             9.1.5.5 United Arab Emirates
                                  9.1.5.5.1 United Arab Emirates market estimates and forecast, 2020 - 2032
Chapter 10. Competitive Analysis
                   10.1. Recent Developments & Impact Analysis, By Key Market Participants
                   10.2. Company/Competition Categorization
                   10.3. Manufacturer’s Landscape
                   10.4. Vendor Landscape
                   10.5. Key Initiatives & Strategic Alliances Analysis
                        10.5.1. Merger & Acquisition Deals
                        10.5.2. Collaborations & Partnerships
                        10.5.3. Business Expansion
                        10.5.4. Technology Collaborations
                   10.6. Public Companies Analysis
                   10.7. Private Companies
                        10.7.1. List of Key Emerging Companies
                        10.7.2. Market Participation Categorization (Market Operations & Weakness)
                        10.7.3. Strategy Framework
                   10.8. Company Profiles
                        10.8.1. Charles River Laboratories
                             10.8.1.1. Company Overview
                             10.8.1.2. Product Benchmarking
                             10.8.1.3. Strategic Initiatives
                        10.8.2. VGXI, Inc
                             10.8.2.1. Company Overview
                             10.8.2.2. Product Benchmarking
                             10.8.2.3. Strategic Initiatives
                        10.8.3. Aldevron.
                             10.8.3.1. Company Overview
                             10.8.3.2. Product Benchmarking
                             10.8.3.3. Strategic Initiatives
                        10.8.4. KANEKA CORPORATION
                             10.8.4.1. Company Overview
                             10.8.4.2. Product Benchmarking
                             10.8.4.3. Strategic Initiatives
                        10.8.5. Nature Technology
                             10.8.5.1. Company Overview
                             10.8.5.2. Product Benchmarking
                             10.8.5.3. Strategic Initiatives
                        10.8.6. Cell and Gene Therapy Catapult
                             10.8.6.1. Company Overview
                             10.8.6.2. Product Benchmarking
                             10.8.6.3. Strategic Initiatives
                        10.8.7. Eurofins Genomics
                             10.8.7.1. Company Overview
                             10.8.7.2. Product Benchmarking
                        10.8.8. Lonza
                             10.8.8.1. Company Overview
                             10.8.8.2. Product Benchmarking
                             10.8.8.3. Strategic Initiatives
                        10.8.9. Luminous BioSciences, LLC
                             10.8.9.1. Company Overview
                             10.8.9.2. Product Benchmarking
                             10.8.9.3. Strategic Initiatives
                        10.8.10. Akron Biotech
                             10.8.10.1. Company Overview
                             10.8.10.2. Product Benchmarking
                             10.8.10.3. Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert